NCT01212627 2021-02-16
Ridaforolimus With Cetuximab: Adv Non-Small Cell Lung, Colorectal, Head & Neck Cancer
Brown University
Phase 1 Terminated
Clinical Trials
5 trialsNCT01431534 2019-03-01
MK-8669-056
Merck Sharp & Dohme LLC
Phase 1 Terminated
NCT00836927 2019-02-18
MK-8669-038
Merck Sharp & Dohme LLC
Phase 2 Terminated
NCT01243762 2018-08-16
A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027)
Merck Sharp & Dohme LLC
Phase 1 Terminated
NCT00818675 2015-01-21
A Study of Ridaforolimus in Non-Small Cell Lung Cancer (NSCLC) Patients With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutations (MK-8669-021 AM1)
Merck Sharp & Dohme LLC
Phase 2 Terminated